Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4813)	7/7/1998 7:23:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Steve! AG3340 just went into pivotal trials ... 500+ patients, PII/III (lead-in dose ranging PII, then continue onto PIII) ... AGPH cut over immediately from PI. They must have some optimism with regard to the product, and must have some basis for that optimism. It's way too early to expect any inklings about AG3340, except that the company appears to be very positive about the product, and is aggressively pursuing its development. But don't expect any news until sometime next year or the following year. That's just inherent in drug development. There's no other company that would tell you otherwise. gotta be patient on this one ... Peter

To: Steve Fancy who wrote (4813)	7/7/1998 10:36:00 PM
From: Steve Fancy	Respond to of 6136

Ok Peter, I'll have to let this go for now, however, I want to go on record as stating one more time that something does not feel right about this drug and the way its been handled and received. Andreas, a fellow I've come to respect from his posts and apparent knowledge in the area agreed on this thread recently... exchange2000.com ...and we were all surprised to learn that they had rather secretly entered Phase II/Phase III a while back, remember? You have to admit, the Phase I results when they were finally released, did absolutely nothing in terms of generating even the slightest bit of excitement that I remember. In any case, my suspicion is on record. No return word from AGPH yet on the inlicensing payments...if and when I receive a response, I'll post it. sf